Newcastle disease virus (NDV)-based vaccines
We use the Newcastle disease virus (NDV) expressing the antigen of interest as viral vector vaccines. We have developed NDV-based SARS-CoV-2 ancestral and variant vaccines (NDV-HXP-S) that could be given systemically (inactivated) or intranasally (live). The inactivated NDV-HXP-S ancestral vaccine is conditionally approved for EUA in Thialand.
Influenza virus vaccines
We develop influenza virus vaccines with improved cross-protection. Our vaccine strategies focused on both the hemagglutin (HA) and the neuraminidase (NA). Our “mosaic” HA-expressing influenza viruses vaccines aim to broaden antibody responses targeting the HA. We also designed and developed viruses with improved “visibility” and abundance of the NA.
Vaccine-induced immune responses in preclinical animal models
We are interested in investigating vaccine-induced humoral and cellular immune responses (B cell and T cell) in the preclinical animal models with a particular interests in mucosal immunity.